




RealRate

PHARMACEUTICAL 2017

PUMA Biotechnology INC
Rank 162 of 308



The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 73% points. The greatest weakness of PUMA Biotechnology INC is the variable Research and Development, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 3.0% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	236,474
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,461
Liabilities, Non-Current	0
Other Assets	11,163
Other Compr. Net Income	134
Other Expenses	0
Other Liabilities	5,505
Other Net Income	585
Other Revenues	0
Property and Equipment	5,153
Research and Development	222,798
Selling, General and Administrative Expense	53,798

Output Variable	Value in 1000 USD
Assets	252,790
Liabilities	42,966
Expenses	276,596
Revenues	0
Stockholders Equity	209,824
Net Income	-276,011
Comprehensive Net Income	-275,944
BaseVar	286,536
ECR before LimitedLiability	123%
Economic Capital Ratio	248%